Graig Suvannavejh analyst GOLDMAN SACHS

Currently out of the existing stock ratings of Graig Suvannavejh, 118 are a BUY (67.43%), 50 are a HOLD (28.57%), 7 are a SELL (4%).

Graig Suvannavejh

Work Performance Price Targets & Ratings Chart

Analyst Graig Suvannavejh, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 58.34% that have a potential upside of 32.42% achieved within 105 days. Previously, Graig Suvannavejh worked at MIZUHO.

Graig Suvannavejh’s has documented 367 price targets and ratings displayed on 35 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IMCR, Immunocore Holdings Ltd at 11-Nov-2024.

Wall Street Analyst Graig Suvannavejh

Analyst best performing recommendations are on ADVM (ADVERUM BIOTECHNOLOGIES).
The best stock recommendation documented was for ADVM (ADVERUM BIOTECHNOLOGIES) at 4/28/2020. The price target of $170 was fulfilled within 7 days with a profit of $48.4 (39.8%) receiving and performance score of 56.86.

Average potential price target upside

ALEC Alector ARQT Arcutis Biotherapeutics  BTAI BioXcel Therapeutics CERE Cerevel Therapeutics Holdings CYTK Cytokinetics FLXN Flexion Therapeutics HALO Halozyme Therapeutics HRMY Harmony Biosciences Holdings INSM Insmed ITCI Intracellular Th JAZZ Jazz Pharmaceuticals PLC KOD Kodiak Sciences ORTX Orchard Therapeutics PLC TGTX TG Therapeutics ATHA Athira Pharma  GMTX Gemini Therapeutics MOR MorphoSys AG ADR RYTM Rhythm Pharmaceuticals XEC Cimarex Energy Co AXSM Axsome Therapeutics RAIN Rain Therapeutics ADVM Adverum Biotechnologies AMLX Amylyx Pharmaceuticals HZNP Horizon Pharma PLC IMCR Immunocore Holdings Ltd IMTX Immatics NV MNTA Momenta Pharmaceuticals PTLA Portola Pharmaceuticals TCDA Tricida AUTL Autolus Therapeutics Ltd EYPT Eyepoint Pharmaceuticals KRTX Karuna Therapeutics TERN Terns Pharmaceuticals VIGL Vigil Neuroscience APLS Apellis Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$35

$30.93 (759.95%)

$35

13 days ago
(07-Nov-2024)

0/7 (0%)

$29.36 (520.57%)

Buy

$15

$10.93 (268.55%)

$8

11 months 6 days ago
(14-Dec-2023)

1/4 (25%)

$7 (87.50%)

128

Buy

$9

$4.93 (121.13%)

$10

1 years 3 days ago
(17-Nov-2023)

1/5 (20%)

$4.69 (108.82%)

24

Sell

$4

$-0.07 (-1.72%)

$9

1 years 1 months 26 days ago
(25-Sep-2023)

2/2 (100%)

$-2.98 (-42.69%)

36

Hold

$10

$5.93 (145.70%)

$10

1 years 3 months 13 days ago
(07-Aug-2023)

1/5 (20%)

$2.64 (35.87%)

332

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Graig Suvannavejh is most bullish on?

Potential upside of $18.78 has been obtained for HRMY (HARMONY BIOSCIENCES HOLDINGS)

Which stock is Graig Suvannavejh is most reserved on?

Potential downside of $3.35 has been obtained for HALO (HALOZYME THERAPEUTICS)

What Year was the first public recommendation made by Graig Suvannavejh?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?